Navigation Links
Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
Date:7/29/2008

t change the underlying course of the disease. It is widely hoped that the next generation of therapies will be disease modifying, that is, they will slow or stop the brain cell death and loss of function caused by Alzheimer's.

"We must develop better treatments for Alzheimer's that go beyond improving symptoms to drugs that actually change the course of the disease. Delaying the onset of Alzheimer's and slowing the progression of the disease means that millions of people would not get Alzheimer's, and that many who do get the disease might only experience mild symptoms. In addition, delaying the onset and slowing the progression of Alzheimer's in the next five years could generate billions of dollars annually in Medicare and Medicaid savings for nursing home care alone," Gandy said.

Dr. Gandy is Mount Sinai Professor of Alzheimer's Disease Research, Professor of Neurology and Psychiatry, and Associate Director of the Alzheimer's Disease Research Center at the Mount Sinai School of Medicine, New York City.

18-Month Phase III Trial Results for Tarenflurbil (Flurizan)

Myriad Genetics announced on June 30, 2008, that its Phase III trial of tarenflurbil (Flurizan) had failed to achieve statistical significance on either of its two primary endpoints, and that the company was abandoning development of the compound for Alzheimer's disease.

"While the results of the trial were certainly disappointing, just because the Flurizan Phase III clinical trial failed, doesn't mean that other amyloid-targeted therapies in the clinical trial pipeline aren't valid. We learn a great deal from every clinical study," Gandy said. "There are many ways to impact amyloid and its role in Alzheimer's. There are other drugs in development that target amyloid with mechanisms of action that are different from this one. One or more of these drugs may ultimately prove successful."

At ICAD 2008, detailed data and results from the trial were presented for the
'/>"/>

SOURCE Alzheimer's Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
5. Controversy About Lack of Placebo Group Decline in Alzheimers Clinical Trials
6. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
11. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... , Aug. 28, 2015 ... and Dr. Ra from Biostar , Published in ... 30% increase of lifespan through multiple IV administration of ... vitality, and life expectancy found , Commercialization within ... have determined the possibility that adult mesenchymal stem cells ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... , SAN DIEGO , July 14 ... the Marketing Authorization Application (MAA) for OraVerse has been accepted ... Kingdom (UK), Germany , Italy , ... and only local anesthesia reversal agent that accelerates the return ...
... 13 Program officials have confirmed that they will announce the ... conference tomorrow in Atlanta .  Georgia Drug Card is being launched ... medications. , , , ... obtain prescription cards at various hospitals, clinics, and other card distribution sites ...
Cached Medicine Technology:Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 2Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 3Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries 4
(Date:8/29/2015)... ... 29, 2015 , ... Next weekend is Labor Day weekend, the last bash ... September 22nd this year). For IT security personnel, it should also mark the perfect ... far more costly than a simple headache. , Joe Caruso, founder and CEO-CTO of ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
(Date:8/28/2015)... Port Richey, FL (PRWEB) , ... August 28, 2015 , ... ... while many potential workers are qualified for the position they are applying for, they ... Because of this, many employers are considering altering drug testing policies in order to ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a non-invasive ... two years, the longest of any cellulite reduction system currently on the market. ... solution for their cellulite, according to Dr. Robert Weiss, director of the premier MD ...
(Date:8/28/2015)... ... ... “ Frequentz ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... product movement from beginning to end. , Businesses benefit greatly from having the ability ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... culling of poultry began in Niger one of the world’s ... an outbreak of deadly// avian flu near its southern border ... culling of all poultry in affected areas on February 28, ... has now appealed for international help, as it lacked the ...
... to a yearly exodus phenomenon of nearly 15,000 nurses, ... raking// in the moolah elsewhere! This has created quite ... on the country’s health services. According to Health Secretary ... 85% of the nursing population, settled in foreign lands, ...
... the Professor Rox Anderson who is a dermatologist at the ... burnt using laser//. Scientists in the US are developing this ... down without affecting the underlying skin. ,They say ... and heart disease. The professor has experimented this laser using ...
... of Bangladesh, Dr Khandker Mosharraf Hossain the manpower in the ... country. ,Addressing a discussion as the chief guest ... World Health Day he said that about 38,206 physicians were ... millions people. The number of nurses to serve the nation ...
... Florida State University study, hospitals can combat spiralling health ... hospital operations. ,According to Ken Lubben, information ... Lakewood Ranch Medical Centre, have already made big investments ... said that, the hospitals are yet to reap any ...
... breast removed to prevent a second bout of cancer don't regret ... one breast but decided to have both breasts removed in order ... said they were still satisfied with their decision, as long as ... by Dr. Ann M. Geiger of Wake Forest University School of ...
Cached Medicine News:Health News:Delayed Start By Niger On Culling Of Poultry 2Health News:Delayed Start By Niger On Culling Of Poultry 3Health News:Technology Can Help Fight Health Care Costs 2Health News:Technology Can Help Fight Health Care Costs 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: